Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhejiang
Clinical trial register · China

Clinical Trials in Zhejiang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Zhejiang Cancer Hospital5 The Third Affiliated hospital of Zhejiang Chinese Medical University3 First Affiliated Hospital of Zhejiang University3 Second Affiliated Hospital of Wenzhou Medical University2 Xiamen Amoytop Biotech Co., Ltd.2
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Zhejiang

47 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC )
NCT07904884ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Acute Myeloid Leukemia
First Affiliated Hospital of Zhejiang University
Not applicable
310
Zhejiang
2026-11-01
Not yet open
Eddingpharm (Zhuhai) Co., Ltd.
Phase 2
144
Harbin, Zhejiang
2026-11
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
420
Beijing, Zhejiang, Yunnan
2026-10-20
Not yet open
First Affiliated Hospital of Ningbo University
Observational
100
Hefei, Zhejiang, Shanghai
2026-10-01
Not yet open
Rongchang Pharmaceuticals Co., Ltd.
Phase 1/2
486
Beijing, Hunan, Zhejiang, Shandong, Shanghai, Shanxi, Tianjin
2026-09-15
Not yet open
18F-S2P PET Imaging in the Evaluation of Large Artery Atherosclerosis
NCT07815860Large-Artery Atherosclerosis (Embolus/Thrombosis)
First Affiliated Hospital of Zhejiang University
Not applicable
200
Zhejiang
2026-09
Recruiting
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
NCT07776522Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
DrugAflibercept
West China Hospital
Phase 2
50
Beijing, Jilin City, Chongqing, Shantou, Zhejiang, Harbin, Zhengzhou, Wuhan
2026-08-31
Not yet open
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Not yet open
Comparing Esketamine and Remazolam With Propofol for Breathing Safety in Pediatric Gastroscopy
NCT07748884Adverse Respiratory Events, Hypoxemia, Children, Gastroscopy
Second Affiliated Hospital of Wenzhou Medical University
Phase 4
120
Zhejiang
2026-08
Not yet open
Red Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility
NCT07653945Bronchoscopic Biopsy, Airway Lesion, Biopsy-related Bleeding
First Affiliated Hospital of Ningbo University
Observational
206
Hefei, Zhejiang, Shanghai
2026-07-01
Recruiting
Suzhou Abogen Biosciences Co., Ltd.
Phase 3
18,000
Jinan, Nanning, Shijiazhuang, Zhejiang
2026-06-27
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
36
Beijing, Henan, Shanghai, Sichuan, Xiamen, Zhejiang
2026-06-10
Recruiting
Bone Management in Pregnancy Outcomes in Epilepsy
NCT07651709Epilepsy, Pregnant Woman, Bone Health
DrugVitamin D
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
80
Zhejiang
2026-06
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Early Phase 1
6
Zhejiang
2026-05
Active, closed
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
132
Zhejiang
2026-03-01
Not yet open
TMS for Improving Cognitive Function in Bipolar Disorder
NCT07414147Bipolar Disorder (BD), Cognitive Impairment
First Affiliated Hospital of Zhejiang University
Not applicable
88
Zhejiang
2026-03-01
Recruiting
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
NCT07492342Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
DrugsFulzerasib·Sintilimab
Jianxing He
Phase 2
30
Beijing, Guangzhou, Zhejiang
2026-01-29
Not yet open
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
30
Zhejiang
2026-01-10
Active, closed
Akeso
Phase 1
108
Zhejiang
2025-12-11
Active, closed
Zhejiang Cancer Hospital
Observational
70
Zhejiang
2025-12-08
Recruiting
Zhejiang Cancer Hospital
Phase 2
118
Zhejiang
2025-11-24
Recruiting
JMT106 Injection in the Treatment of Advanced Solid Tumors
NCT07275073Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
Shanghai JMT-Bio Inc.
Phase 1
200
Zhejiang
2025-09-25
Recruiting
Changhai Hospital
Phase 4
1,366
Shanghai, Zhejiang
2025-09-15
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
290
Zhejiang
2025-09-10
Recruiting
A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects
NCT07319364Fecal Microbiota Transplantation (FMT), Gastrointestinal Neoplasms, Antineoplastic Agents, Drug-related Side Effects and Adverse Reactions
DrugFecal Microbiota Transplantation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
90
Zhejiang
2025-09-01
Recruiting
Effect of Bright Light Therapy on Idiopathic Scoliosis
NCT07424703Idiopathic Scoliosis, Eveningness, Delayed Sleep Phase
Second Affiliated Hospital of Wenzhou Medical University
Not applicable
120
Zhejiang
2025-09-01
Recruiting
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Recruiting
China Colorectal Cancer Screening Trial 1 (C-Cost1)
NCT07090291Colorectal Cancer, Advanced Adenoma
Zhejiang University
Not applicable
60,300
Guandong, Guangdong, Hebei, Nanjing, Shanghai, Sichuan, Zhejiang
2025-08-08
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
Zuoyi Jiao
Phase 3
454
Beijing, Fuzhou, Lanzhou, Zhejiang, Xi'an
2025-06-16
Recruiting
RenJi Hospital
Observational
114
Beijing, Guangdong, Guizhou, Jiangsu, Shanghai, Sichuan, Tianjin, Zhejiang
2025-03-13
Recruiting
Zhejiang Cancer Hospital
Observational
600
Zhejiang
2025-03-01
Recruiting
Beijing Anzhen Hospital
Not applicable
15,360
Zhejiang
2025-03-01
Recruiting
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Zhejiang Cancer Hospital
Phase 2
20
Zhejiang
2025-01-04
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
Recruiting
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1
77
Beijing, Zhejiang, Shandong, Shanghai
2024-10-29
Active, closed
Zhejiang Cancer Hospital
Observational
100
Zhejiang
2024-09-01
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Recruiting
A Study of JMT203 in Patients With Cancer Cachexia
NCT06868849Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia
Shanghai JMT-Bio Inc.
Phase 1/2
307
Zhejiang
2024-05-15
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Phase 3
58
Zhejiang
2024-04-01
Recruiting
Shanghai Chest Hospital
Not applicable
100
Zhengzhou, Beijing, Chengdu, Linyi, Nanchang, Shanghai, Shijiazhuang, Zhejiang
2024-01-01
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
304
Shanghai, Zhejiang
2023-11-20
Active, closed
Belite Bio, Inc
Phase 3
429
Beijing, Chengdu, Guandong, Zhejiang
2023-07-27
Active, closed
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Recruiting
Xing Xie
Phase 1/2
50
Zhejiang
2020-07-01
Active, closed
Epizyme, Inc.
Phase 3
599
Fuzhou, Xiamen, Guiyang, Zhejiang, Shijiazhuang, Zhengzhou, Changsha, Changchun
2020-06-11
Rows per page Showing 1–47 of 47
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/zhejiang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 47 of those studies with a site in Zhejiang.

How many clinical trials are recruiting in Zhejiang?

29 of the 47 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 11 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhejiang), 47 studies
PhaseStudiesRecruitingShare
Not applicable12725.5%
Phase 38517%
Phase 27614.9%
Observational6212.8%
Phase 16512.8%
Phase 1/25310.6%
Phase 4214.3%
Early Phase 1102.1%

Most active sponsors

Lead sponsors with the most studies (Zhejiang)
Lead sponsorStudiesRecruiting
Zhejiang Cancer Hospital53
First Affiliated Hospital of Zhejiang University30
The Third Affiliated hospital of Zhejiang Chinese Medical University32
First Affiliated Hospital of Ningbo University20
Second Affiliated Hospital of Wenzhou Medical University21
Second Affiliated Hospital, Zhejiang University, School of Medicine21
Shanghai JMT-Bio Inc.22
The Fourth Affiliated Hospital of Zhejiang University School of Medicine21
Xiamen Amoytop Biotech Co., Ltd.22
Akeso10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.